Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE We interrogated The Cancer Genome Atlas for transcriptional signatures and mutations enriched in promyelocytic leukemia and/or obesity and confirmed correlation between body mass and FLT3 mutations in promyelocytic leukemia cohorts by logistic regression. 31515354 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE Single-nucleotide variant (SNV) analysis in 77 children (80 samples) with RARA rearrangement showed recurrent alternations of primary APL in FLT3, WT1, USP9X, NRAS, and ARID1A, with a strong potential for involvement in pathogenesis, and WT1 as the only recurrently mutated gene in relapsed APL. 30575821 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE Data were assessed for age, sex, ethnicity, body mass index percentile, initial white blood cell count, peripheral blood blast count, and platelet count, hemoglobin value, partial thromboplastin time, prothrombin time, fibrinogen level, serum creatinine level, APL morphology subtype (classic vs. hypogranular variant M3v), and FLT3 gene mutations. 31613846 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE We aimed to determine the frequencies of the PML-RARα transcripts and FLT3-ITD mutations in APL patients to evaluate their prognostic implications and also to analyze their impact on disease outcome. 30803552 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE The additional somatic mutations in APL mainly involve FLT3, WT1, NRAS, KRAS, ARID1B and ARID1A genes. 31635329 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE This study highlights FLT3-internal tandem duplications as a prognostic factor in APL and proposes consideration of prior antitubulin therapy as a prognostic factor in non-APL AML. 30715157 2019
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE The National Comprehensive Cancer Network (NCCN) defines the following types of acute myeloid leukemia (AML) as favorable-risk: acute promyelocytic leukemia with t(15;17) (APL); AML with core-binding factor (CBF) rearrangements, including t(8;21) and inv(16) or t(16;16) without mutations in KIT (CBF-KIT<sup>wt</sup>); and AML with normal cytogenetics and mutations in NPM1 (NPM1<sup>mut</sup>); or biallelic mutations in CEBPA (CEBPA<sup>mut/mut</sup>), without FLT3-ITD. 29310020 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE We present a case of an 18-year-old female who was diagnosed with AML (FLT3 (Fms like tyrosine kinase 3) and PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) translocation-negative) and after initial treatment with a standard induction regimen of cytarabine and daunorubicin (3+7 regimen), her bone marrow showed blast cells less than 5% and dense aggregates/sheets of atypical/immature mast cells with immunohistochemical stain CD117+ve and toluidine blue positive in mast cell aggregates. 30800544 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE To the best of our knowledge, this is the first report of a novel three-way translocation of 6p21 and a FLT3-ITD mutation involved with APL. 30344754 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE To explore the relationship between FLT3 (encoding Fms related tyrosine kinase 3) internal tandem duplication (ITD) mutations with the prognosis of acute promyelocytic leukemia. 29251252 2018
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE Here, we describe a case of APL with high white blood cell counts in blood tests and hypogranular variant morphology in bone marrow, together with fms-like tyrosine kinase-3 with internal tandem duplication mutations (FLT3-ITD), and bcr-3 isoform of PML-RARα. 28125133 2017
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE Subjects with BCL11A transcript levels at diagnosis exceeding the median value of 2.434 (±3.423 SD; 25th-75th inter-quartile range, 1.33-4.29) had higher WBC levels, a greater proportion of bone marrow myeloblasts, were more likely to be FAB M0 subtype, less likely to be FAB M3 subtype, more likely to be in the intermediate cytogenetic risk cohort, less likely to have a complex karyotype and more likely to have DNMT3A(R882) and FLT3-ITD mutations than subjects with transcript levels below the median value. 26707798 2016
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. 27133819 2016
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE These observations indicate that extended immunophenotypic and molecular characterization of APL at diagnosis including evaluation of CD2, CD56, and CD34 antigens and of FLT3 mutations may help to better design risk-adapted treatment in this disease. 26920716 2016
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE FLT3-ITD mutations were found in 10 patients (19.2%), being more common in adults than in children (21.1% vs. 14.3%) and more prevalent in patients with acute promyelocytic leukemia (AML-M3) than AML-non M3 (4 of 10 AML-M3 vs. 6 of 42 AML- non M3 patients). 27797250 2016
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease CTD_human Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. 26285909 2015
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE This study provides further evidence that FLT3-ITDs carriers constitute a biologically distinct group of APL patients. 25530565 2015
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE We analyzed 245 newly diagnosed adult patients with APL treated on intergroup trial C9710 and evaluated previously defined biological and prognostic factors and their relationship to FLT3 mutations and to additional karyotypic abnormalities. 24160850 2014
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease CTD_human We analyzed 245 newly diagnosed adult patients with APL treated on intergroup trial C9710 and evaluated previously defined biological and prognostic factors and their relationship to FLT3 mutations and to additional karyotypic abnormalities. 24160850 2014
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE In addition, FLT3-ITD may independently predict a shorter survival in patients with APL treated with ATRA and anthracycline-based chemotherapy. 24981688 2014
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE To the best of our knowledge, this is the first report of a de novo APL with a chromosome translocation t(7;16)(q31,q22) together with a t(15;17)(q22;q21) and FLT3-ITD mutation. 23651981 2013
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse. 23816818 2013
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE The prevalence and prognostic significance of FLT3/Mut have not been well defined in childhood acute promyelocytic leukemia (APL). 22378655 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 GeneticVariation disease BEFREE Moreover, the characterisation of specific molecular abnormalities provides the basis for targeted therapies, such as all trans retinoic acid (ATRA) and arsenic trioxide treatment in acute promyelocytic leukaemia or tyrosine kinase inhibitors in AML with FLT3 mutations. 22791509 2012
Entrez Id: 2322
Gene Symbol: FLT3
FLT3
0.400 Biomarker disease BEFREE Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia. 21298367 2012